News and Trends 1 Jun 2022 New treatment option available for Dravet syndrome Global biopharma company UCB says the UK’s National Institute for Healthcare Excellence (NICE) has issued a positive Final Appraisal Determination (FAD) for its FINTEPLA (fenfluramine) oral solution. FINTEPLA is used for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines for patients two years of age and older. […] June 1, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2022 GSK to acquire clinical-stage biopharmaceutical company Affinivax GSK plc is set to acquire Affinivax, Inc., a clinical-stage biopharmaceutical company based in Cambridge, Boston, Massachusetts, for a $2.1B upfront payment and up to $1.2B in potential development milestones. Affinivax is developing a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines. Pneumococcal disease includes pneumonia, meningitis, bloodstream infections, and […] June 1, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2022 Therapeutic RNA company receives additional funding UK biotech company Transine Therapeutics, which is developing a novel class of therapeutic RNAs, has successfully raised £4.6M ($5.8M) in additional seed funding. The financing was led by new investor Epidarex Capital with participation from existing investor the Dementia Discovery Fund (DDF). Transine said the additional funds will enable it to further develop its SINEUP […] May 31, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2022 Evotec adds cell therapy manufacturing facility through Rigenerand takeover German headquartered life science company Evotec SE has acquired 100% of the capital of Rigenerand Srl, an Italian cell technology company, for €23M ($24.7M). Founded in 2009 as a spin-off of the University of Modena and Reggio Emilia in Italy, Rigenerand is based in Medolla, Italy, about 100 km south of Evotec’s Campus Levi-Montalcini in […] May 31, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2022 Award to help NRG Therapeutics develop new Parkinson’s and Motor Neuron Disease treatments UK neuroscience company NRG Therapeutics Ltd has received a Biomedical Catalyst (BMC) award to fund preclinical development of its small molecule disease-modifying medicines for the treatment of Parkinson’s disease, motor neuron disease (MND) and other debilitating chronic neurodegenerative disorders. The £2.68M ($5.8M) early-stage BMC award part-funded by the government-backed agency Innovate UK will support a […] May 31, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2022 ANGLE and U.S. urology group to undertake prostate cancer study ANGLE plc has signed a master clinical study agreement with Solaris Health Holdings, LLC and joinder agreements with MidLantic Urology LLC, to collaborate and conduct clinical studies in prostate cancer and as a potential route to market in the U.S. Alongside Solaris affiliate MidLantic Urology, UK-headquartered ANGLE will initiate clinical studies aimed at detecting prostate […] May 31, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 30 May 2022 Decentralized autonomous organizations are changing how biotechs are run Built on the emerging ecosystems of Web3 and blockchain, decentralized autonomous organizations (DAOs) allow communities to collectively fund and advance biotech research. The majority of biotech companies are highly centralized with much of the data siloed away in their proprietary databases. Companies have no incentives to openly share this data, which slows down progress in […] May 30, 2022 - 8 minutesmins - By Sachin Rawat Share WhatsApp Twitter Linkedin Email
News and Trends 27 May 2022 Up to 500 new jobs as Lilly invests $2.1B in new manufacturing sites Eli Lilly and Company is boosting its manufacturing footprint by investing $2.1 billion in two new U.S. sites. The new facilities are located at Indiana’s LEAP Lebanon Innovation and Research District in Boone County. David A. Ricks, Lilly’s chair and CEO, said: “These new sites will add capacity in support of our growing pipeline of […] May 27, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 May 2022 HotSpot looks to boost cancer therapy pipeline with Excelra partnership U.S. biotech company HotSpot Therapeutics, Inc. is looking to increase its drug development and discovery efforts by partnering with Indian data and digital insights company Excelra. HotSpot discovers and develops small molecule allosteric therapies for the treatment of cancer and autoimmune diseases. What are allosteric therapies? In the journal ACS Medicinal Chemistry Letters, Ahmed F. […] May 27, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 May 2022 Companies partner on early lung cancer detection blood test U.S. company CorePath Laboratories is partnering with U.K. diagnostics firm Cizzle Biotechnology on an early-stage lung cancer test for the U.S. Lung cancer is the leading cause of cancer deaths in the U.S., making up almost 25% of all cancer deaths. Each year, more people die of lung cancer than of colon, breast, and prostate […] May 27, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 May 2022 Blue Lake Biotechnology RSV vaccine gets FDA fast track U.S. company Blue Lake Biotechnology, Inc. has received U.S. Food and Drug Administration (FDA) Fast Track designation for its respiratory syncytial virus (RSV) intranasal vaccine. The biopharma company, a subsidiary of CyanVac LLC, develops vaccines using a parainfluenza virus 5 (PIV5)-based vector. The FDA Fast Track designation applies to BLB-201, a vaccine for the prevention […] May 27, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 May 2022 Animal-free milk company Imagindairy reaches $28M in funding Israeli foodtech startup Imagindairy, Ltd., developer of animal-free dairy milk proteins, has secured an additional $15M in its extended seed-round to bring the total investment so far to $28M. The alt-protein company creates animal-free milk proteins from microorganisms through precision-fermentation technology, which allows the production of a wide range of dairy analogs, from raw milk […] May 27, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email